- Conditions
- HIV Infections, Human Immunodeficiency Virus
- Interventions
- Dexelvucitabine
- Drug
- Lead sponsor
- Incyte Corporation
- Industry
- Eligibility
- 16 Years to 75 Years
- Enrollment
- 250 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006
- U.S. locations
- 10
- States / cities
- Long Beach, California • Brandon, Florida • Fort Lauderdale, Florida + 7 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 25–48
of 24
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Hidradenitis Suppurativa (HS)
- Interventions
- Povorcitinib
- Drug
- Lead sponsor
- Incyte Corporation
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 617 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2026
- U.S. locations
- 61
- States / cities
- Phoenix, Arizona • Scottsdale, Arizona • Fort Smith, Arkansas + 51 more
- Conditions
- Acute Lymphoblastic Leukemia, ALL, Childhood, ALL
- Interventions
- Ruxolitinib, Cyclophosphamide, Cytarabine, Mercaptopurine, Vincristine, Pegaspargase, Rituximab, Methotrexate (Intrathecal Administration), Methotrexate (Intravenous Administration), Dexamethasone, Doxorubicin, Thioguanine, Methotrexate Oral Product
- Drug
- Lead sponsor
- University of Chicago
- Other
- Eligibility
- 18 Years to 39 Years
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2027
- U.S. locations
- 2
- States / cities
- Chicago, Illinois • Dallas, Texas
- Conditions
- Renal Insufficiency, Kidney Diseases
- Interventions
- INCB054707
- Drug
- Lead sponsor
- Incyte Corporation
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 25 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022 – 2023
- U.S. locations
- 3
- States / cities
- Tustin, California • Orlando, Florida • San Antonio, Texas
- Conditions
- Hematologic and Lymphocytic Disorder
- Interventions
- Allogeneic Hematopoietic Stem Cell Transplantation, Busulfan, Cyclophosphamide, Fludarabine, Itacitinib, Tacrolimus, Thiotepa
- Procedure · Drug
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 31 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2027
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Type 2 Diabetes
- Interventions
- INCB013739, Placebo comparator matching INCB013739, Metformin
- Drug
- Lead sponsor
- Incyte Corporation
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 302 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2009
- U.S. locations
- 62
- States / cities
- Birmingham, Alabama • Artesia, California • Calabasas, California + 54 more
- Conditions
- Graft-versus-host Disease (GVHD)
- Interventions
- Tacrolimus (Tac), Methotrexate (MTX), Ruxolitinib (Rux), Cyclophosphamide, Mycophenolate mofetil (MMF)
- Drug
- Lead sponsor
- Incyte Corporation
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 572 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2031
- U.S. locations
- 30
- States / cities
- Palo Alto, California • San Francisco, California • Miami, Florida + 23 more
- Conditions
- Chronic Graft-versus-host-disease
- Interventions
- Itacitinib, Extracorporeal Photopheresis (ECP)
- Drug · Device
- Lead sponsor
- University of Utah
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 3 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2023
- U.S. locations
- 1
- States / cities
- Salt Lake City, Utah
- Conditions
- Ovarian Cancer
- Interventions
- INCB123667, Investigator's choice of chemotherapy
- Drug
- Lead sponsor
- Incyte Corporation
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 466 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2029
- U.S. locations
- 48
- States / cities
- Anchorage, Alaska • Tucson, Arizona • Duarte, California + 41 more
- Conditions
- NonSegmental Vitiligo
- Interventions
- Povorcitinib, Placebo
- Drug
- Lead sponsor
- Incyte Corporation
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 450 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2027
- U.S. locations
- 33
- States / cities
- Birmingham, Alabama • Montgomery, Alabama • Fountain Valley, California + 25 more
- Conditions
- Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Recurrent Acute Myeloid Leukemia, Recurrent Secondary Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia, Refractory Secondary Acute Myeloid Leukemia
- Interventions
- Azacitidine, Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Echocardiography Test, Punch Biopsy, Questionnaire Administration, Ruxolitinib, Venetoclax
- Drug · Procedure · Other
- Lead sponsor
- Jennifer Saultz
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 51 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2027
- U.S. locations
- 3
- States / cities
- Columbus, Ohio • Portland, Oregon • Dallas, Texas
- Conditions
- Breast Cancer
- Interventions
- Ruxolitinib, Capecitabine, Placebo
- Drug
- Lead sponsor
- Incyte Corporation
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 149 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2017
- U.S. locations
- 80
- States / cities
- Birmingham, Alabama • Chandler, Arizona • Sedona, Arizona + 77 more
- Conditions
- Graft Vs Host Disease, Graft-versus-host-disease, Graft Versus Host Disease
- Interventions
- Ruxolitinib, Abatacept
- Drug
- Lead sponsor
- Washington University School of Medicine
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 41 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 1
- States / cities
- St Louis, Missouri
- Conditions
- Hematologic Malignancies
- Interventions
- Cyclophosphamide, Mycophenolate Mofetil, Ruxolitinib, Tacrolimus
- Drug
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2029
- U.S. locations
- 7
- States / cities
- Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more
- Conditions
- Type 2 Diabetes
- Interventions
- INCB019602, Placebo, Metformin
- Drug
- Lead sponsor
- Incyte Corporation
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 48 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2009
- U.S. locations
- 22
- States / cities
- Phoenix, Arizona • Tucson, Arizona • Chula Vista, California + 19 more
- Conditions
- Glioma, Glioblastoma
- Interventions
- Epacadostat, Bevacizumab, Radiation therapy, Retifanlimab
- Drug · Radiation
- Lead sponsor
- Washington University School of Medicine
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 51 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2025
- U.S. locations
- 4
- States / cities
- Phoenix, Arizona • Rochester, Minnesota • St Louis, Missouri + 1 more
- Conditions
- Steroid Refractory GVHD, Graft Vs Host Disease
- Interventions
- Itacitinib, Tocilizumab
- Drug
- Lead sponsor
- Columbia University
- Other
- Eligibility
- 18 Years to 99 Years
- Enrollment
- 1 participant
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2021
- U.S. locations
- 2
- States / cities
- New York, New York
- Conditions
- Glioblastoma, Brain Cancer, Glioblastoma Multiforme, Glioblastoma Multiforme of Brain, Glioblastoma Multiforme, Adult, MGMT-Unmethylated Glioblastoma, MGMT-Methylated Glioblastoma
- Interventions
- Ruxolitinib, Temozolomide, Radiation Therapy
- Drug · Radiation
- Lead sponsor
- Baptist Health South Florida
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 190 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2030
- U.S. locations
- 2
- States / cities
- Miami, Florida • New York, New York
- Conditions
- Systemic Lupus Erythematosus
- Interventions
- Baricitinib, Placebo
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 778 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2021
- U.S. locations
- 39
- States / cities
- Gilbert, Arizona • Phoenix, Arizona • Tucson, Arizona + 33 more
- Conditions
- Myeloproliferative Neoplasm (MPN)
- Interventions
- Ruxolitinib
- Drug
- Lead sponsor
- Incyte Corporation
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 73 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2018
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Polycythemia Vera
- Interventions
- ruxolitinib tablets, Best Available Therapy (BAT)
- Drug · Other
- Lead sponsor
- Incyte Corporation
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 222 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2018
- U.S. locations
- 28
- States / cities
- Birmingham, Alabama • Scottsdale, Arizona • Pomona, California + 25 more
- Conditions
- HIV Infections
- Interventions
- INCB009471, Placebo comparator
- Drug
- Lead sponsor
- Incyte Corporation
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 45 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2007
- U.S. locations
- 6
- States / cities
- Los Angeles, California • Washington D.C., District of Columbia • Orlando, Florida + 3 more
- Conditions
- Acute Myeloid Leukemia, Acute Lymphoid Leukemia, Mixed Phenotype Acute Leukemia, Myelodysplastic Syndromes
- Interventions
- ORCA-T
- Drug
- Lead sponsor
- Stanford University
- Other
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2026
- U.S. locations
- 1
- States / cities
- Palo Alto, California
- Conditions
- Vitiligo
- Interventions
- Ruxolitinib cream, Vehicle Cream
- Drug
- Lead sponsor
- Incyte Corporation
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2023
- U.S. locations
- 6
- States / cities
- Fountain Valley, California • Irvine, California • Washington D.C., District of Columbia + 3 more